Salute e Benessere

Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic…

Successful meeting with FDA enables advancement into pivotal development with Privosegtor in Acute Optic Neuritis (AON) and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)Oculis will launch the PIONEER Program, which includes multiple global trials intended to support registrations in AON and NAIONCompany to host conference call and webcast at 8:30 AM ET today Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations...

COSRX Wraps Up "COSRX Glow Market" Pop-Ups Successfully in Paris & London…

According to COSRX, both pop-ups saw overwhelming engagement, with long queues in Paris and a steady buzz in London, drawing a combined total of nearly 20,000 visitors. In collaboration with Moida K-Beauty, the events were held at the stores inherently located in high-traffic areas popular among beauty-conscious and K-beauty enthusiasts. Across both cities, COSRX combined interactive brand experiences with on-site sales, further enhancing accessibility to its best-selling and newly launched…

Final Chance to Glow: COSRX Tops Amazon Prime Big Deal Days with Advanced Snail…

LIMITED Prime Big Deal Days: COSRX Essentials Winning Over CustomersNow available as exclusive Amazon Prime Big Deal Days offers, these Amazon's Choice winners and category No. 1 bestsellers showcase what beauty lovers across Europe can't get enough of. LIMITED Prime Big Deal Days: COSRX Essentials Winning Over CustomersNow available as exclusive Amazon Prime Big Deal Days offers, these Amazon's Choice winners and category No. 1 bestsellers showcase what beauty lovers acrossEuropecan't...

Onco3R Therapeutics Announces Completion of First Cohort in Phase 1 Trial of…

Dosing of first cohort in Phase 1 trial of O3R-5671 complete with no adverse findingsOn track for full data read out in the first half of 2026Discovery and preclinical data on O3R-5671 selected for oral presentation at United European Gastroenterology Week 2025Leuven, Belgium. October 6, 2025. Onco3R Therapeutics, a clinical-stage immunology and oncology biotech company dedicated to transforming patients’ lives with best-in-class medicines, today announced the successful...

Olympus and W. L. Gore & Associates Enter into International Distribution…

Gore and Olympus bring together talent and technology, and this agreement presents opportunities to elevate the standard of care, as both companies share a history of delivering innovative interventional therapeutic products to improve outcomes for patients. With the addition of the GORE® VIABIL® Biliary Endoprosthesis for endoscopic placement to its existing portfolio of stents designed for the biliary tree, Olympus offers healthcare professionals and their patients a broad range of GI devices.

Implantica Successfully Completes MDSAP Recertification Audit

Applications for Canada and Brazil are planned for submission in 2026, following completion of the U.S. Food and Drug Administration (FDA) inspections at Implantica's Malta site and its manufacturing facilities. Applications forCanadaandBrazilare planned for submission in 2026, following completion of the U.S. Food and Drug Administration (FDA) inspections at Implantica'sMaltasite and its manufacturing facilities. Additionally, Implantica has received confirmation from the FDA...

FDA Lifts Clinical Hold on NUZ-001

Dr Michael Thurn, Managing Director and CEO, commented: "The FDA's clearance of our IND application marks a significant milestone in our mission to bring NUZ-001 closer to patients living with ALS. This achievement reflects both our unwavering commitment to rigorous scientific and clinical development and the tireless dedication of our team. DrMichael Thurn, Managing Director and CEO, commented: "The FDA's clearance of our IND application marks a significant milestone in our mission…

Trogenix announces £70 million / $95 million Series A financing to drive…

Trogenix's breakthrough Odysseus® platform targets cancer cells to deliver precision therapies with curative “one and done” potential across multiple aggressive, treatment-resistant cancersFinancing round led by IQ Capital with participation from founding investor 4BIO Capital, returning investors Cancer Research Horizons and the National Brain Tumor Society’s Brain Tumor Investment Fund, and new investors Eli Lilly and Company, Meltwind, LongeVC, and Calculus CapitalCancer Research...

BlueNord: Preliminary Production for September 2025

The base assets, Dan, Gorm, and Halfdan hubs, delivered 19.2 mboepd net to the Company. Dan and Halfdan performed as expected, while the Gorm hub experienced operational challenges related to compressors and the water injection system. The operator is currently working to resolve the issues, and BlueNord expects full production from Gorm to resume in the near term. Preliminary production for third quarter 2025 for the base assets was 20.2 mboepd which is slightly below guidance of 21.0 – 23.0…

VALNEVA Declaration of shares and voting rights: September 30, 2025

VALNEVADeclaration of shares and voting rightsSeptember 30, 2025__________________________________________________________________________________________Company name: VALNEVA Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France) Regulated market of Euronext Paris - Compartment B Declaration date: October 6, 2025 Number of sharescomposing the share capital of ValnevaTotal number of voting rights including suspended voting rights* Description of the...

Roche receives CE Mark for AI-based Kidney Klinrisk Algorithm(1) and launches…

Roche, in collaboration with KlinRisk, Inc, has received CE-mark for the first AI-based risk stratification tool for assessment of progressive decline in kidney function.This tool will be launched as part of Roche’s new chronic kidney disease (CKD) algorithm panel to support care across the stages of the disease which affects 700 million people globally.Clinicians can use the CKD panel (Kidney Klinrisk Algorithm and Kidney KFRE Algorithm) to evaluate a patient’s risk of kidney...

Nyxoah Announces First U.S. Commercial Patients Implanted with Genio® System

Nyxoah Announces First U.S. Commercial Patients Implanted with Genio® SystemEarly Commercial Launch Demonstrates Strong Physician Demand, Successful Pre-Authorizations, and Widespread Payor CoverageMont-Saint-Guibert, Belgium – October 6, 2025 7:00 CET / 1:00 ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced that the first U.S. commercial patients have been...

Fagron receives Brazilian antitrust clearance for Purifarma and Injeplast…

Regulated information - inside information Nazareth (Belgium)/Rotterdam (The Netherlands), 6 October 2025 – 7:00 AM CET Fagron receives Brazilian antitrust clearance for Purifarma and Injeplast acquisitionsFagron, the leading global player in pharmaceutical compounding, announces that the Brazilian competition authority, CADE, has granted clearance for the previously announced acquisitions of Purifarma and Injeplast in Brazil.The clearances represent an important step forward in...

Why Travel for Wellness: ASICS Reveals 15 Minutes of Movement Can Boost Your…

According to Euromonitor, the global demand for wellness holidays has surged by 33% in the last year [2], with the Global Wellness Institute finding that people spend an average of $1,764 for a week away, 41% more than standard travel.[3] However, new global research by ASICS[4], surveying 11,000 people who recently took a wellness holiday, reveals that whilst people travel on average 1,920km for their wellness holidays[4], they don't always deliver. Two-thirds (67%) said their wellness holiday…

EANM'25: Metabolically active visceral fat linked to aggressive endometrial…

Researchers from Haukeland University Hospital and the University of Bergen analysed PET/CT scans of 274 women with endometrial cancer, measuring glucose uptake in visceral fat as an indicator of metabolic activity. They found that women with higher metabolic activity - assessed by average glucose uptake in visceral fat tissue - were more likely to present with advanced stage disease and lymph node metastases. Researchers from Haukeland University Hospital and theUniversity of Bergen...

Human Papilloma Virus/HPV Test and Pap Smear/Test Market worth US$3.94 billion…

Browse in-depth TOC on "HPV Testing and Pap Test Market" Browse in-depth TOC on "HPV Testing and Pap Test Market" 311 - Tables 53 - Figures 257 - Pages By test type,the HPV testing and Pap test market is segmented into HPV testing and Pap tests. In 2024, HPV testing accounted for the dominant share of the market. This dominance is attributed to the growing global shift toward HPV testing as the primary screening method for cervical cancer, supported by its higher...

2025 "Jiangsu Traditional Chinese Medicine Goes Global" European Cultural Tour…

In his remarks, Zhao Ming, Deputy Director of the Cyberspace Administration of Jiangsu Province, described TCM as a "cultural treasure" of Chinese civilization that embodies the philosophies and health traditions of the East. He noted that Jiangsu has long been a center for TCM development and exchange—from Xu Fu's ancient voyages in search of medicinal herbs to Zheng He's maritime expeditions. In recent years, the "Jiangsu Traditional Chinese Medicine Goes Global" initiative…

Publication relating to transparency notifications

REGULATED INFORMATIONPublication relating to transparency notificationsMont-Saint-Guibert(Belgium), October 3, 2025 , 10:30 pm CET / 4:30 pm ET –In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below.Vestal Point CapitalOn October 1, 2025, Nyxoah received a transparency notification from Vestal Point Capital...

Cosmos Health Expands Sky Premium Life Into $1Bn+ Kuwait Market; Signs Exclusive…

Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that its subsidiary, SkyPharm S.A., has entered into an exclusive distribution agreement, dated as of September 28, 2025, with Diyar United for the marketing and sale of its Sky Premium Life® line of nutraceuticals in Kuwait.Diyar United is a respected distributor in Kuwait with extensive healthcare experience. Its strong network,...

Leo Cancer Care Plans to Integrate TibaRay Linacs into Future Grace Photon…

The integration of TibaRay's high-efficiency linac technology will be studied as part of Grace's development program. TibaRay's accelerators are designed to deliver higher dose rates than conventional systems, opening the possibility for new treatment paradigms such as FLASH radiotherapy, while also offering a more compact footprint that aligns well with Leo Cancer Care's upright treatment approach. The integration of TibaRay's high-efficiency linac technology will be studied as part of…

Press release: Transparency Notification from Shareholder

Transparency Notification from ShareholderGhent, Belgium – 3 October 2025 – Sequana Medical NV (Euronext Brussels: SEQUA)(the " Company " or " SequanaMedical "), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces today that it received a transparency notification in relation to the entity listed below, notifying the number of voting rights attached to the shares mentioned next to its name in the table below…

OXURION : Information on the Total Number of Voting Rights (Denominator)…

Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital Commitment[1]. Leuven, BELGIUM – 3 October, 2025 – 06:00 PM CET – In accordance with article 15 of the Belgian Act of May 2, 2007 on the disclosure of…

Virbac : Declaration of the number of shares and voting rights 09/2025

DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial Market Authority – Autorité des Marchés Financiers)Quotation place: Euronext Paris Compartiment A ISIN code: FR0000031577DateTotal number of shares representing the share capitalTotal number of voting rightsSeptember, 30 20258 390 660Gross total of voting...

Oral Contraceptive Pills Market Size to Reach US$ 38.16 Bn by 2033, Driven by…

The oral contraceptive pills (OCPs) market is driven by the high prevalence of unintended pregnancies, which account for nearly half of all pregnancies globally. According to WHO (August 2024), around 73 million induced abortions occur annually, with 61% of unintended and 29% of all pregnancies ending in abortion. Alarmingly, 45% of these are unsafe, underscoring the urgent need for reliable and accessible contraceptive options. The oral contraceptive pills (OCPs) market is driven by the high...

Altri Comunicati